US 11,514,517 · Application 16/678,952 · Granted Nov 29, 2022
US 11,514,517
Scenario gamification to provide improved mortgage and securitization
Estimated expiration
October 4, 2038
12y 24d remaining
Earliest effective filing
Apr 24, 2018
+ 20 years
Apr 24, 2038
PTA +163d
Oct 4, 2038
No TD
—
Final
Oct 4, 2038
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- November 8, 2019
- Earliest effective filing
- April 24, 2018
- Issue date
- November 29, 2022
- PTA
- +163 days
- Base expiry (before PTA)
- April 24, 2038
April 24, 2018 + 20 years = April 24, 2038 + 163 PTA days = October 4, 2038
- Continuation-in-part of application 15/961,809, filed Apr 24, 2018, issued as US 11,232,489
- PRO62/903,587 — Provisional — not used for base term
- PRO62/815,968 — Provisional — not used for base term
- PRO62/758,335 — Provisional — not used for base term
- PRO62/489,351 — Provisional — not used for base term
- PRO62/489,351 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 16/678,952 · US 11,514,517
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,514,517: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11514517Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.